Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net step therapy coverage & prior auth | Op…
    Ask Trek AI about this page
    CurrentHealth NetPolicy N/A

    2026 Step Therapy Criteria

    Customize your policy alerts

    Sign up for all Health Net policy alerts

    Know when Health Net releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Health Net's 2026 step therapy requirements for covered antidepressants, antipsychotics (oral), dextromethorphan/bupropion, and trazodone products; applies to prior authorization and coverage determinations for members under this payer.

    Policy Summary
    PayerHealth Net
    Policy2026 Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionDocument prior medication trials showing the required number of Step 1 agents (e.g., at least a 1-day supply in the prior 180 days) or an allowed exception when requesting Step 2 coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4therapy groups
    2-stepstep levels
    180look-back days
    allowedsuicidal ideation exception

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    inv-01: Antidepressant Initial/Step therapy — Antidepressants — Covered when the following are met

    Antidepressants — Covered when the following are met

    Antidepressant Step 2 coverage: Coverage for Step 2 antidepressant products (Step 2 list) is provided if ONE Step 1 drug has been tried (at least a 1-day supply in the prior 180 days).1 trial / 180 days

    Exceptions: Approve Exxua without prerequisite trial for suicidal ideation, or if patient is currently/previously taking Exxua.

    inv-02: Oral antipsychotics Initial/Step therapy — Oral antipsychotics — Covered when the following are met

    Oral antipsychotics — Covered when the following are met

    Fanapt coverage: Coverage for Fanapt (Step 2) requires that TWO Step 1 oral antipsychotic drugs were tried (each at least a 1-day supply in the prior 180 days).2 trials / 180 days

    Approve if the member is currently taking Fanapt or has taken Fanapt in the past.

    inv-03: Dextromethorphan/bupropion Initial/Step therapy — Dextromethorphan/bupropion — Covered when the following are met

    Dextromethorphan/bupropion — Covered when the following are met

    Auvelity coverage: Coverage for Auvelity requires trial of a generic SSRI or SNRI AND bupropion (each at least a 1-day supply in the prior 180 days).SSRI/SNRI + bupropion; 180 days

    Approve Auvelity without prerequisite trials if suicidal ideation is present, or if patient is currently/previously taking Auvelity.

    inv-04: Trazodone Initial/Step therapy — Trazodone — Covered when the following are met

    Trazodone — Covered when the following are met

    Raldesy coverage: Coverage for Raldesy oral solution (Step 2) requires prior trial of Step 1 trazodone tablet products (at least a 1-day supply in the prior 180 days).Step 1 trial required (1-day supply / 180 days)

    Document trial of trazodone 100 mg or 150 mg (tablet); tablet strengths listed also include 50 mg.

    inv-05: Initial coverage criteria for Raldesy — Covered when ONE of the following is met:

    Covered when ONE of the following is met:

    Coverage for Raldesy: Approve Raldesy (10 mg/mL oral solution) if the patient has tried a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days).at least a 1-day supply in prior 180 days

    Step 1 tablet strengths listed: 50 mg, 100 mg, 150 mg

    Swallowing impairment exception: Approve Raldesy if the patient has difficulty swallowing tablets or cannot swallow tablets.

    Exception to prior tablet trial requirement

    Current or prior Raldesy use: Approve if the patient is currently taking Raldesy or has taken Raldesy at any time in the past.

    Allows continuation without tablet trial

    The policy does not list separate clinical exclusions beyond the stated step therapy rules and the enumerated exceptions. Coverage limitations are governed by the step requirements for each drug group and the documented exceptions for current/prior use or suicidal ideation; no additional disorder-specific or diagnosis-based exclusions are specified in these sections.

    None explicitly stated in this section.

    Initial Therapy Criteria

    inv-32: Antidepressant initial therapy — Antidepressant Step 1 products

    Antidepressant Step 1 products

    Step 1 antidepressant trial: At least one Step 1 antidepressant agent (listed Step 1 agents) must have been tried (at least a 1-day supply in the prior 180 days) to meet Step 2 coverage criteria.1 trial

    Includes listed bupropion formulations, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine.

    inv-33: Antipsychotic initial therapy — Oral antipsychotic Step 1 products

    Oral antipsychotic Step 1 products

    Step 1 antipsychotic trials: Two different Step 1 oral antipsychotics (listed Step 1 agents) must be tried (each at least a 1-day supply in the prior 180 days) before Step 2 antipsychotic coverage.2 trials

    A trial of the brand name equivalent of a generic Step 1 product counts toward the requirement.

    inv-34: Dextromethorphan/bupropion initial therapy — Dextromethorphan/bupropion Step 1 products

    Dextromethorphan/bupropion Step 1 products

    SSRI/SNRI + bupropion requirement: Trial of a generic SSRI or SNRI AND bupropion is required prior to Auvelity coverage (each at least a 1-day supply in the prior 180 days).2 agents

    Step 1 includes listed generic SSRIs/SNRIs and bupropion formulations.

    inv-35: Initial therapy for Raldesy — Initial coverage requires trial of generic trazodone tablet formulation unless exception applies

    Initial coverage requires trial of generic trazodone tablet formulation unless exception applies.

    Step 1 trial: Patient must have tried a tablet dosage form of generic trazodone (at least a 1-day supply in the prior 180 days).at least a 1-day supply in prior 180 days

    Tablet strengths listed in policy: 50 mg, 100 mg, 150 mg

    Step 2: If Step 1 satisfied or exception documented, Raldesy (10 mg/mL oral solution) may be approved.

    Raldesy is listed as Step 2

    Continuation Therapy Criteria

    inv-36: Continuation therapy — Continuation allowed without prior tablet trial when patient is currently taking or has previously taken Raldesy

    Continuation allowed without prior tablet trial when patient is currently taking or has previously taken Raldesy.

    Continuation: Approve continuation if patient is currently taking Raldesy or has taken Raldesy at any time in the past.

    No prior tablet trial required for ongoing users.

    Step Therapy Summary

    RequirementDetails
    One Step 1 trial required
    Coverage for Step 2 antidepressant products is provided if ONE Step 1 drug has been tried (defined as at least a 1-day supply in the prior 180 days). Exceptions: approve Exxua without prerequisite trial for suicidal ideation or if patient is currently/previously taking Exxua.
    RequirementDetails
    Two Step 1 trials required
    Coverage for Fanapt (Step 2 oral antipsychotic) requires that TWO different Step 1 oral antipsychotic drugs have been tried (each at least a 1-day supply in the prior 180 days). Approve if the member is currently taking Fanapt or has taken Fanapt in the past.
    RequirementDetails
    SSRI/SNRI plus bupropion required
    Coverage for Auvelity requires prior trials of a generic SSRI or SNRI AND bupropion (each at least a 1-day supply in the prior 180 days). Exception: approve Auvelity without prerequisite trials if the patient has suicidal ideation, or if the patient is currently/previously taking Auvelity.
    RequirementDetails
    Trazodone Step 1 trial required
    Coverage for Raldesy (Step 2 oral solution) implies prior trial of Step 1 trazodone products (e.g., trazodone 100 mg or 150 mg tablets) before Step 2 coverage is approved.
    StepRequired agent or condition
    Step 1
    Trial of a generic trazodone tablet (50 mg, 100 mg, or 150 mg) — defined as at least a 1-day supply in the prior 180 days.
    Step 2
    Raldesy oral solution (10 mg/mL) — may be approved if Step 1 trial documented, or if an exception applies (difficulty swallowing tablets, or patient is currently/previously taking Raldesy).

    Provider Actions & Documentation Requirements

    Prior Authorization

    Antidepressants — Step 1 trial required

    Step 2 antidepressant coverage requires documentation that the patient tried at least one Step 1 antidepressant (defined as at least a 1-day supply within the prior 180 days) unless the Exxua exception applies for suicidal ideation or current/prior Exxua use.

    • Trial definition: at least a 1-day supply in the prior 180 days.
    • Exception: Approve Exxua without prerequisite trial if patient has suicidal ideation, or if currently/previously taking Exxua.
    Prior Authorization

    Antipsychotics — two Step 1 trials required

    Coverage for Step 2 oral antipsychotics (e.g., Fanapt) requires prior trials of two different Step 1 oral antipsychotics (each defined as at least a 1-day supply in the prior 180 days) unless the member is currently taking Fanapt or has taken it in the past.

    • Each Step 1 trial must be at least a 1-day supply within the prior 180 days.
    • A trial of the brand-name equivalent of a generic Step 1 product counts.
    • Approve if currently or previously taking Fanapt.
    Prior Authorization

    Auvelity — prerequisite trials required

    Auvelity (dextromethorphan/bupropion) requires prior trials of a generic SSRI or SNRI AND bupropion (each at least a 1-day supply in the prior 180 days) before Step 2 coverage, unless the patient has suicidal ideation or is currently/previously taking Auvelity.

    • Required: one generic SSRI or SNRI trial PLUS a bupropion trial (each ≥1-day supply in prior 180 days).
    • Exception: approve without prerequisite trials for suicidal ideation or current/prior Auvelity use.
    Prior Authorization

    Prior authorization for Raldesy

    Prior authorization for Raldesy requires evidence of a trial of an approved Step 1 trazodone tablet (at least a 1-day supply in the prior 180 days) per the step sequence, or documentation of an allowed exception such as difficulty swallowing tablets or current/prior use of Raldesy.

    • Step 1 requirement: tablet dosage form of generic trazodone (50 mg, 100 mg, or 150 mg) tried within prior 180 days.
    • Exceptions: swallowing impairment or current/prior Raldesy use allow approval without tablet trial.
    Step Therapy

    Antidepressants step therapy

    Step 2 antidepressant products are covered only after a documented trial of one Step 1 antidepressant (at least a 1-day supply in the prior 180 days) unless an exception (suicidal ideation or current/prior Exxua use) applies.

    • Step 1 drugs include listed generics (Bupropion SR/XL, Citalopram, Duloxetine, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Venlafaxine).
    • Trial look-back: at least a 1-day supply within prior 180 days.
    Step Therapy

    Oral antipsychotics step therapy

    Coverage for Fanapt (Step 2 oral antipsychotic) requires documented trials of two different Step 1 oral antipsychotics (each at least a 1-day supply in the prior 180 days) unless the member is currently or previously taking Fanapt.

    • Step 1 agents are the listed oral antipsychotics in the policy (chunks 8–9).
    • Each Step 1 trial must meet the 1-day supply in prior 180 days definition.
    Step Therapy

    Dextromethorphan/bupropion step therapy

    Coverage for Auvelity (Step 2 dextromethorphan/bupropion) requires prior trials of a generic SSRI or SNRI plus bupropion (each at least a 1-day supply in the prior 180 days), unless the patient has suicidal ideation or is currently/previously taking Auvelity.

    • Step 1 agents are the listed generic SSRIs/SNRIs and bupropion products (chunk 13).
    • Each required trial must be at least a 1-day supply within the prior 180 days.
    Step Therapy

    Trazodone step therapy

    Trazodone step therapy requires a trial of listed Step 1 trazodone tablets (100 mg or 150 mg; 50 mg also listed in details) before approval of Raldesy oral solution (Step 2), unless an exception applies.

    • Step 1: trazodone 100 mg or 150 mg tablets (50 mg tablet also noted in details).
    • Step 2: Raldesy 10 mg/mL oral solution — approve if Step 1 trial documented or exception applied.
    Step Therapy

    Step therapy sequence

    The policy enforces a two-step sequence for trazodone → Raldesy: Step 1 is trial of generic trazodone tablets (50 mg, 100 mg, or 150 mg; at least a 1-day supply in the prior 180 days); Step 2 is Raldesy oral solution (10 mg/mL) if Step 1 criteria are met or an allowed exception is documented.

    • Document tablet trial: at least a 1-day supply within the prior 180 days.
    • Allowed exceptions: difficulty swallowing tablets or current/prior Raldesy use.
    Documentation Required

    Antidepressant documentation

    For antidepressant Step 2 requests, include documentation showing a trial of at least one Step 1 antidepressant (at least a 1-day supply in the prior 180 days) or documentation that an exception applies (suicidal ideation or current/prior Exxua use).

    • Record dates, agent name, and quantity to confirm at least a 1-day supply in the prior 180 days.
    • If relying on an exception, document suicidal ideation or evidence of current/prior Exxua use.
    Documentation Required

    Antipsychotic documentation

    For Step 2 oral antipsychotic requests, provide documentation of trials of two different Step 1 oral antipsychotics (each at least a 1-day supply in the prior 180 days) or documentation that the member is currently/previously taking Fanapt.

    • Document agent names, dates, and supply to meet the 1-day supply/180-day look-back.
    • If approving based on current/prior Fanapt use, include evidence of prior Fanapt therapy.
    Documentation Required

    Dextromethorphan/bupropion documentation

    For Auvelity requests, document prior trials of a generic SSRI or SNRI AND bupropion (each at least a 1-day supply in the prior 180 days), or documentation of suicidal ideation or current/prior Auvelity use to justify an exception.

    • Provide agent names, dates, and dispensed days' supply to confirm each trial met the 1-day supply/180-day requirement.
    • If exception claimed, document suicidal ideation or evidence of current/prior Auvelity.
    Documentation Required

    Required documentation

    Document a prior medication trial of a generic trazodone tablet (at least a 1-day supply within the prior 180 days) to support Raldesy initial coverage, or document inability to swallow tablets or current/prior Raldesy use to support an exception.

    • Tablet strengths listed: 50 mg, 100 mg, 150 mg — record dates and days' supply.
    • If patient cannot swallow tablets, include clinical documentation of swallowing impairment.
    Denial Risk

    Antidepressants Step 1 requirement

    Coverage will be denied for Step 2 antidepressant requests if the prerequisite Step 1 drug has not been tried (defined as at least a 1-day supply in the prior 180 days) and no allowable exception is documented.

    • Ensure one Step 1 trial is documented or provide exception evidence (suicidal ideation or current/prior Exxua use) to avoid denial.
    Denial Risk

    Antipsychotics Step 1 requirement

    Coverage for Fanapt (Step 2 antipsychotic) will be denied unless documentation shows two Step 1 oral antipsychotic trials (each at least a 1-day supply in the prior 180 days) or evidence the member is currently/previously taking Fanapt.

    • Each Step 1 trial must meet the 1-day supply/180-day definition to avoid denial.
    • If member has current/prior Fanapt use, include supporting evidence.
    Denial Risk

    Dextromethorphan/bupropion Step requirements

    Coverage for Auvelity (Step 2) will be denied unless the record documents trials of a generic SSRI or SNRI plus bupropion (each at least a 1-day supply in the prior 180 days), unless an exception (suicidal ideation or current/prior Auvelity use) is documented.

    • Confirm dates and days' supply for both the SSRI/SNRI and bupropion trials to meet the requirement.
    • If claiming an exception, include documentation of suicidal ideation or prior/current Auvelity therapy.
    Denial Risk

    Prior tablet trial requirement

    Coverage for Raldesy is contingent on prior use of a tablet dosage form of generic trazodone (at least a 1-day supply within the prior 180 days) unless the patient has difficulty swallowing tablets or is currently/previously taking Raldesy.

    • If no prior tablet trial is documented, include clinical evidence of swallowing impairment or evidence of current/prior Raldesy use to avoid denial.
    • Tablet trial must meet the 1-day supply/180-day look-back.

    Coding & Look-back Definitions

    inv-08: Prior trial look-back — at least a 1-day supply in the prior 180 days
    Look‑back periodAt least a 1‑day supply in the prior 180 days
    Applies toStep 1 trials for antidepressant Step 2 coverage (bupropion SR/XL, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine)
    inv-09: prior trial look-back (alternate chunk) — at least a 1-day supply in the prior 180 days
    Look‑back period (tablet trial)At least a 1‑day supply in the prior 180 days (tablet dosage form of generic trazodone)
    Applies toPrior tablet trial requirement before Raldesy (oral solution) initial coverage
    Exception notesException if patient has difficulty swallowing tablets or is currently/previously taking Raldesy
    inv-28: Trial definition — A trial is defined as at least a 1-day supply of a specified Step 1 drug in the prior 180 days.
    Trial definitionA trial is defined as at least a 1‑day supply of a specified Step 1 drug in the prior 180 days.
    ContextUsed across step therapy groups to determine prior use (antidepressants, antipsychotics, dextromethorphan/bupropion, trazodone)
    Evidence requirementPharmacy claims or documentation must show at least a 1‑day supply within the prior 180 days to count as a trial

    Definitions & Product Notes

    inv-29: Exception — suicidal ideation — For specified products (Exxua, Auvelity), approval may be granted without prerequisite trials if the patient has suicidal ideation, or if other listed exceptions apply.
    Products with suicidal‑ideation exceptionExxua and Auvelity may be approved without prerequisite trials if the patient has suicidal ideation.
    Continuation/current‑use exceptionAlso approve if the patient is currently taking the product or has taken it in the past.
    ScopeException applies only to the specified brand products noted in the policy (Exxua, Auvelity)
    inv-30: Raldesy 10 mg/mL oral solution (trazodone) — product identifier and reference
    Product nameRaldesy 10 mg/mL oral solution (trazodone)
    FormulationOral solution, 10 mg/mL
    Role in step therapyListed as Step 2 for trazodone; requires prior tablet trial of generic trazodone unless exception applies
    inv-31: trazodone 50 mg, 100 mg, 150 mg tablets — generic trazodone tablet strengths referenced as Step 1
    Tablet strengths listedtrazodone 50 mg, 100 mg, and 150 mg tablets (generic trazodone)
    Role in step therapyThese generic trazodone tablet strengths are the Step 1 agents required before Raldesy Step 2 coverage (at least a 1‑day supply in prior 180 days)
    Documentation noteEvidence must show a tablet dosage form trial (≥1‑day supply in prior 180 days) unless patient cannot swallow tablets or is current/previous Raldesy user

    Background

    This document defines Health Net’s step therapy (prior therapy) requirements used to manage utilization of selected psychotropic drug groups: antidepressants, oral antipsychotics, dextromethorphan/bupropion combination products, and trazodone. For covered Step 2 agents the policy generally requires documented prior trials of listed Step 1 agents defined as at least a 1-day supply in the prior 180 days. Specific exceptions allow approval without prerequisite trials for certain brand products when the member has suicidal ideation or is currently/previously taking the product (for example, Exxua and Auvelity), and a swallowing-impairment or ongoing-use exception applies to Raldesy.

    Policy Summary
    PayerHealth Net
    Policy2026 Step Therapy Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateMay 1, 2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionDocument prior medication trials showing the required number of Step 1 agents (e.g., at least a 1-day supply in the prior 180 days) or an allowed exception when requesting Step 2 coverage.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy SummaryProvider Actions & Documentation RequirementsCoding & Look-back DefinitionsDefinitions & Product NotesBackground